Automating Eurofins DiscoverX Cell-Based Bioassays on Tecan’s Fluent Automation Workstation

Automating Eurofins DiscoverX Cell-Based Bioassays on Tecan’s Fluent Automation Workstation
Year:
2021


Through early discovery, screening, characterization, and particularly for market release and commercialization of biologics, drug candidates require physiologically relevant, functional cell-based assays as characterization tools that attest to their therapeutic activity. This biological activity is a critical attribute for drug candidates, and can be accurately measured using cell-based potency assays. Moreover, analyzing potency is a key measurement for the final market release of a therapeutic product such as a biologic or a biosimilar.